Share on twitter
Share on LinkedIn
Share on Facebook
Email to a friend
Print page
This statement is a response to new advice from the MHRA regarding use of cyproterone acetate and risk of meningioma.
This document is up-to-date
A Danish database study suggests that children born to women who have used hormonal contraception (HC) in the three months prior to conception or in early pregnancy are at increased risk of developing childhood non-lymphoid leukaemia compared with children whose mothers have never used HC. The FSRH CEU provides a critical appraisal of the study in this statement.
This document is up-to-date
Gliomas are glial cell tumours which can occur in the spinal cord or the brain and are the most common type of brain tumour. They vary greatly in their likely rate of growth, differentiation and prognosis. Glioblastoma multiforme is the most common and most aggressive primary brain tumour.
This document is up-to-date
Various news stories have reported the findings detailed in the AAN press release which stated that compared to women who did not use hormonal contraceptives, women who did, were 35 percent more likely to develop Multiple Sclerosis and that the findings suggested that hormonal contraception may be contributing to the rise in the rate of MS among women.
This document is up-to-date
Much recent media attention has been given to the subject of a potential association between hormonal contraception and depression. The FSRH CEU monitors and reports relevant emerging evidence. A new systematic review published in Contraception examines the existing evidence relating to risk of depression associated with use of progestogen-only contraception (POC).1 The authors of the review conclude that the bulk of the evidence does not support an association between use of POC and depression based on validated measures. Meta-analysis was not possible due to the heterogeneity of studies.
This document is up-to-date
This statement is a CEU response to a study published in JAMA Psychiatry titled Association of Hormonal Contraception with Depression.
This document is up-to-date
FSRH's Clinical Effectiveness Unit (CEU) reviews an observational study published in the New England Journal of Medicine. The study reports that, in the Danish study population, women who were currently using any method of hormonal contraception* (HC) or had done so within the last 6 months were 20% more likely to be diagnosed with breast cancer than those who had never used HC.
This document is up-to-date
This statement responds to a recent study that reported that women who had used intrauterine contraception (IUC) were over one third less likely to experience invasive cervical cancer than women who had not used IUC. The study has received media attention and the FSRH CEU considered it important to put the findings into perspective. January 2018
This document is up-to-date
This statement reviews and summarises the available evidence regarding the effect of contraception on weight. Looking at each method individually, the FSRH CEU advises clinicians regarding proven and theoretical associations between contraceptive options and weight/BMI.
This document is up-to-date
Following a presentation at the annual meeting of the American Academy of Ophthalmology a number of media reports have reported a possible link between use of combined oral contraception (COC) and glaucoma. There is limited data investigating combined hormonal contraceptives on glaucoma. One cohort study suggested that 5 or more years of COC use was associated with a 25% increase in the risk of glaucoma. Two UK cohort studies did not find consistent evidence of an increased risk.
This document is up-to-date
